Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0506 • ACR Convergence 2023
Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study
Nelly Ziade¹, Noura Abbas², Lina El Kibbi³, Avin Maroof⁴, Bassel Elzorkany⁵, Nizar Ani⁶, ASAL ADNAN⁷, NABAA IHSAN JAWAD AWADH⁷, Faiq Gorial⁸, Nada Alchama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Hannawi¹², Saed Atawnah¹³, HUSSEIN HALABI¹⁴, Manal Al-Mashaleh¹⁵, Laila Aljazwi¹⁶, Ahmed Abogamal¹⁷, laila Ayoub¹⁸, Elyes Bouajina¹⁹, Rachid Bahiri²⁰, Sahar Saad²¹, Maha Sabkar²¹, Krystel Aouad²², Laure Gossec²³ and Ihsane Hmamouchi²⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Kurdistan University Hawler, Erbil, Iraq, ⁵Private (BZRC), Cairo, Egypt, ⁶Baghdad College of Medicine, Baghdad, Iraq, ⁷Baghdad Teaching Hospital, Baghdad, Iraq, ⁸University of Baghdad, Baghdad, Iraq, ⁹Ebn Al Nafiss Hospital, Damascus, Syria, ¹⁰Faculty of Medicine El Mahdi Si Ahmed, Blida, Algeria, ¹¹University of Jordan, Amman, Jordan, ¹²Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ¹³Al ahli hospital, Hebron, Palestine, Hebron, Palestinian Territories, ¹⁴King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia, ¹⁵Royal Medical Services, Amman, Jordan, ¹⁶Tripoli, Tripoli, Libya, ¹⁷Saudi German Hospital Dubai, Dubai, United Arab Emirates, ¹⁸University of Tripoli, Tripoli, Libya, ¹⁹Farhat Hached Hospital of Sousse, Sousse, Tunisia, ²⁰Department of Rheumatology, El Ayachi Hospital Medical University, Sale, Morocco, ²¹King Hamad University Hospital, Bahrain, Bahrain, ²²Saint George Hospital University Medical Center, Beirut, Lebanon, ²³Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco
Background/Purpose: In patients with psoriatic arthritis (PsA), discordance between physicians and patients when assessing disease activity has been described as frequent, mainly in European and…
Abstract Number: 0965 • ACR Convergence 2023
Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Louise Linde², Lykke Ørnbjerg¹, Simon Horskjær Rasmussen¹, Johan Askling³, Brigitte Michelsen⁴, Daniela Di Giuseppe³, Johan Karlsson Wallman⁵, Bente Glintborg⁶, Anne Gitte Loft⁷, Miguel Bernardes⁸, Carolina Ochôa Matos⁹, Dan Nordstrom¹⁰, Laura Kuusalo¹¹, Burkhard Moeller¹², Michael Nissen¹³, Bjorn Gudbjornsson¹⁴, Thorvardur Love¹⁵, Florenzo Iannone¹⁶, Tore Kvien¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Gary Macfarlane²⁰, Marleen van de Sande²¹, Merete Hetland¹ and Mikkel Østergaard²², ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁷Aarhus University, Horsens, Denmark, ⁸Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁹Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹²Inselspital - University Hospital Bern, Bern, Switzerland, ¹³Geneva University Hospitals, Geneva, Switzerland, ¹⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹⁵Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Universitario Gregorio Marañón, Madrid, Spain, ²⁰Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Disease Activity index for PSoriatic Arthritis based on 66/68 joints (DAPSA66/68) and the Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP)…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1429 • ACR Convergence 2023
Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Carlo Selmi¹, Fausto Salaffi², Sibel Aydin³, Enrique Soriano⁴, Emmanouil Rampakakis⁵, Mohamed Sharaf⁶, Miriam Zimmermann⁷, Frederic Lavie⁸, Peter Nash⁹ and Philip J. Mease¹⁰, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ²Polytechnic University of Marche, Department of Clinical and Molecular Sciences, Carlo Urbani Hospital, Ancona, Italy, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA-5Ts is a simple multidimensional composite measure, assessing pain, fatigue, physical function, skin problems, and depression, recently developed to measure overall health in PsA…
Abstract Number: 1643 • ACR Convergence 2023
Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
Nikita Looby¹, Max Kotlyar², Chiara Pastrello², Darshini Ganatra¹, Vathany Kulasingam³, Igor Jurisica⁴ and Vinod Chandran⁵, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory immune-mediated musculoskeletal skin disease that affects approximately 25% of psoriasis patients causing progressive disability. As a heterogeneous disease,…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…
Abstract Number: 2235 • ACR Convergence 2023
Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
Quan Li¹, Darren O'Rielly¹, Kari Jenkins¹, Dianne Codner¹, Dafna Gladman², Amanda Dohey¹, Igor Jurisica³, Vinod Chandran⁴ and Proton Rahman⁵, ¹Memorial University, St. John's, NL, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada
Background/Purpose: Approximately 30 to 40% of patients are primary non-responders, and the response rate declines after each successive biological therapy. The primary aim is to…
Abstract Number: 2251 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Koji Kato⁶, Arathi Setty⁶, Tianming Gao⁶, Diane Caballero⁷, Ralph Lippe⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0491 • ACR Convergence 2023
Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound
rodrigo garcía salinas¹, Jonatan Mareco², Santiago Ruta², RONALD PEREZ², Felica Almada² and Sebastián Juan Magri³, ¹Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: The psoriasis- to- psoriatic arthritis (PsA) transition offers a unique opportunity to identify individuals at increased risk of developing PsA and to implement preventive…
Abstract Number: 0507 • ACR Convergence 2023
The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis
Antoni Chan and NiSoe Nwe, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom
Background/Purpose: Patient-reported outcome measures (PROMs) are important tools for evaluating disease activity, functional status, and quality of life in patients with psoriatic arthritis (PsA). The…
Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abisola Olopoenia¹, Ashley Martin², Kate Orroth³, Cynthia Deignan⁴, Myriam Cordey⁵ and Dafna Gladman⁶, ¹Cerner Enviza, North Kansas City, MO, ²BluePath Solutions, Los Angeles, CA, ³Amgen, Inc., Manhattan Beach, CA, ⁴Amgen, Inc., Agoura Hills, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
Abstract Number: 1413 • ACR Convergence 2023
Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST
Philip J. Mease¹, Alexis R Ogdie², Kristina Callis Duffin³, Jyotsna Reddy⁴, Rebecca Wang⁴, Shauna Jardon⁴ and Laura Coates⁵, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³University of Utah, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: The modified minimal disease activity (MDA-Joints) is a novel composite endpoint to assess disease activity and treatment effect in PsA based on a criteria…
Abstract Number: 1430 • ACR Convergence 2023
A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients
Esther Espartal López¹, Xabier Michelena Vegas², Sara Marsal Barril¹, Alex Rovira³, Deborah Pareto³ and Alba Erra Duran¹, ¹Vall Hebron University Hospital, Rheumatology Department, Barcelona, Spain, ²Hospital Universitari Vall Hebron, Barcelona, Spain, ³Vall Hebron University Hospital, Section of Neuroradiology (Department of Radiology, IDI), Barcelona, Spain
Background/Purpose: Inflammatory cytokines can alter the way the central nervous system processes pain as shown in patients with rheumatoid arthritis. However, the relationship between TNFα…
Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Alba Boix-Amorós¹, Rebecca Blank², Adam Cantor¹, Jesus Sanz³, Ana Gutiérrez-Casbas⁴, Jordi Gratacos Masmitja⁵, Iago Rodríguez -Lago⁶, Elisa Trujillo⁷, Ignacio Marin-Jimenez⁸, Zulema Plaza⁹, Marta Domínguez¹⁰, Jose Federico Diaz-Gonzalez¹¹, Juan D Canete¹², Jose Scher¹³ and Jose Clemente¹, ¹Icahn School of Medicine, New York, NY, ²New York University, New York, NY, ³Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁵University Hospital Parc Taulí, Sabadell, Spain, ⁶Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Public Health System, Madrid, Spain, ⁹Universidad Autónoma de Madrid, Madrid, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Universitario de Canarias, La Laguna, Spain, ¹²Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹³New York University School of Medicine, New York, NY
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].